Trilogy International Partners Inc T.TRL.WT.A

Aytu Business Update - Natesto.

[swickedman]

Exerpt from Aytu Q3 Business update. 

"Acquiring U.S. commercial rights to Natesto (testosterone) Nasal Gel from Acerus Pharmaceuticals positions Aytu to make a substantial impact within the $2 billion testosterone replacement therapy market for men with hypogonadism (low testosterone, or "Low T").  Natesto's unique product profile confers significant competitive advantages, both in terms of increased convenience for users and the fact that Natesto is the only topical testosterone product on the market without a black box safety warning for the risk of testosterone transference.  Aytu is currently scaling its urology-centric sales force in preparation for a planned July 2016 product launch, and we will dedicate substantial commercial resources to assertively convert prescriptions from current topical testosterone products and gain prescriptions from newly diagnosed Low T patients."